GYRE · Gyre Therapeutics, Inc.
$6.89
-0.13 (-1.85%)
At close · Aug 21
Market Cap
$778.90M
Shares
111.51M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Weiguo Ye | Chief Operating Officer | $5,023,749 |
| Ping Zhang | Interim Chief Executive Officer | $4,096,623 |
| Han Ying | Senior Vice President, Science and Former Chief Executive Officer | $353,315 |
| Ruoyu Chen | Chief Financial Officer | $285,583 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Han Ying | Chief Executive Officer | $2,888,140 |
| Ruoyu Chen | Chief Financial Officer | $650,516 |
| Weiguo Ye | Chief Operating Officer | $332,619 |
| Charles Wu | Former Chief Executive Officer | $15,350 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Weiguo Ye | Chief Operating Officer | $274,617 |
| Ruoyu Chen | Chief Financial Officer | $208,162 |
| Charles Wu | Former Chief Executive Officer | $106,152 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Charles Wu | Chief Executive Officer | $78,347 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Nassim Usman | President and Chief Executive Officer Clinton ^^ Musil Chief Financial Officer | $1,409,622 |
| Howard Levy | M.B.B.Ch., Ph.D., M.M.M Chief Medical Officer | $826,709 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Nassim Usman | President and Chief Executive Officer Clinton ^^ Musil Chief Financial Officer | $1,198,865 |
| Howard Levy | M.B.B.Ch., Ph.D., M.M.M Chief Medical Officer | $733,018 |
| Fletcher Payne | Former Chief Financial Officer | $471,208 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Nassim Usman | President and Chief Executive Officer | $2,442,314 |
| Howard Levy | M.B.B.Ch., Ph.D., M.M.M Chief Medical Officer | $1,198,847 |
| Fletcher Payne | Former Chief Financial Officer | $969,476 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Maxwell Kirkby | Class II director | Appointed | 2026-07-16 |
| Claire Weston, Ph.D. | Class III director | Appointed | 2026-07-16 |
| Yue Xiong, Ph.D. | Class I director | Appointed | 2026-07-16 |
| Ruoyu Chen | Chief Financial Officer | Resigned | 2026-05-04 |
| Thomas Eastling | Chief Financial Officer | Appointed | 2026-05-04 |
| Ying Luo | Class I director | Appointed | 2026-05-04 |
| Songjiang Ma | President | Resigned | 2026-05-04 |
| Ying Luo | Chief Executive Officer and President | Appointed | 2026-05-04 |
| Songjiang Ma | director | Resigned | 2026-05-04 |
| Thomas Eastling | director | Resigned | 2026-05-04 |
| Dan Weng, M.D. | Class II director | Appointed | 2025-08-22 |
| Han Ying | Chief Executive Officer | Resigned | 2025-08-11 |
| Han Ying | member of the Board | Resigned | 2025-08-11 |
| Ping Zhang | Interim Chief Executive Officer | Appointed | 2025-08-11 |
| Ping Zhang | lead independent director of the Board | Appointed | 2025-01-06 |
| Songjiang Ma | Chairman of the Gyre Pharmaceuticals Board | Appointed | 2025-01-06 |
| Ping Zhang | Class I director | Appointed | 2025-01-06 |
| Ying Luo, Ph. D. | Chairman and a member of the board of directors | Resigned | 2025-01-06 |
| Rodney Nussbaum | chair of the Audit Committee | Appointed | 2024-08-08 |
| David Epstein | Class II director | Appointed | 2024-08-08 |
| Nassim Usman, Ph.D. | member of the Company's Board of Directors | Resigned | 2024-07-05 |
| Rodney Nussbaum | Class III director | Appointed | 2024-03-21 |
| Charles Wu | member of the board of directors | Resigned | 2023-12-15 |
| Charles Wu | Chief Executive Officer | Retired | 2023-12-15 |
| Han Ying | Chief Executive Officer | Appointed | 2023-12-15 |
Key facts
CIK
1124105
CUSIP
403783103
13F (30d)
53 filings
53 filers
Visit website
Investor relations